A traumatic brain injury occurs when a blow or jolt of the head creates sudden damage to the brain. Traumatic brain injuries can vary from being mild concussions to more severe and permanent brain damage. The most common causes of a traumatic brain injury include falls and road injuries (auto, bicycle, pedestrian).

It is estimated that more than 69 million individuals throughout the world sustain a traumatic brain injury each year and that in the U.S., traumatic brain injury is a contributing factor to a third of all injury-related US deaths. Because of their occurrence rates to falling, children and older adults are at most risk to sustaining a TBI.

The most common symptoms of traumatic brain injuries include confusion and disorientation, difficulty remembering new information, headaches, dizziness, blurry vision, nausea and vomiting. While treatment for mild TBI may include rest and medication, severe TBI may require intensive care and life saving-surgery.

The effective treatment of TBI represents one of the largest unmet needs in public health. Major progress in understanding the pathophysiology of TBI is being done by the One Mind supported TRACK-TBI study that is working to confirm FDA approved biomarkers that will enable researchers to more effectively match patients to clinical trials and in the end provide precise targets for the development of new therapies and devices to treat TBI.

By supporting the TRACK-TBI study and other major TBI related initiatives such as the TBI Endpoints Development Initiative, InTBIR (the International Initiative for Traumatic Brain Injury Research), and GAIN, One Mind is playing a significant role in accelerating treatments for TBI.